Blueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($1.35), $0.34 better than the analyst estimate of ($1.69). Revenue for the quarter came in at $51.5 million versus the consensus estimate of $26.07 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.